Literature DB >> 1979002

Alpha-1 adrenergic receptor binding and adrenergic-stimulated cyclic AMP production in rat cerebral cortex after chronic lithium treatment.

T L Casebolt1, X H Li, R S Jope.   

Abstract

Administration to rats of dietary lithium for 30 days was followed by evaluation of alpha-1 adrenergic receptor binding and of adrenergic-stimulated cyclic AMP (cAMP) accumulation in rat cerebral cortex. Chronic lithium treatment did not alter the binding characteristics of [3H]prazosin or the proportion of alpha-1 adrenergic receptor subtypes distinguished by chlorethyl-clonidine (CEC) pretreatment in rat cerebral cortical membranes. Accumulation of cAMP in cortical slices incubated with adrenergic agonists was unaffected in lithium-treated rats. These results demonstrate that chronic lithium treatment-induced reduction of norepinephrine (NE)-stimulated phosphoinositide (PI) hydrolysis (Casebolt and Jope, 1987) is not due to changes in the alpha-1 adrenergic receptor and is more sensitive to in vivo lithium treatment than is adrenergic-stimulated cAMP accumulation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1979002     DOI: 10.1007/bf01272762

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  29 in total

1.  Identification of subtypes of [3H]prazosin-labelled alpha 1 receptor binding sites in rat brain.

Authors:  A L Morrow; G Battaglia; A B Norman; I Creese
Journal:  Eur J Pharmacol       Date:  1985-02-26       Impact factor: 4.432

2.  A simple and sensitive saturation assay method for the measurement of adenosine 3':5'-cyclic monophosphate.

Authors:  B L Brown; J D Albano; R P Ekins; A M Sgherzi
Journal:  Biochem J       Date:  1971-02       Impact factor: 3.857

3.  Fluoride-stimulated adenylate cyclase activity in rat brain following chronic treatment with psychotropic drugs.

Authors:  P H Andersen; R Klysner; A Geisler
Journal:  Neuropharmacology       Date:  1984-04       Impact factor: 5.250

4.  Effects of lithium in vitro on noradrenaline-induced cyclic AMP accumulation in rat cortical slices after reserpine-induced supersensitivity.

Authors:  M E Newman; P Lichtenberg; R H Belmaker
Journal:  Neuropharmacology       Date:  1985-04       Impact factor: 5.250

5.  Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding.

Authors:  A L Morrow; I Creese
Journal:  Mol Pharmacol       Date:  1986-04       Impact factor: 4.436

6.  Long-term lithium treatment selectively reduces receptor-coupled inositol phospholipid hydrolysis in rat brain.

Authors:  T L Casebolt; R S Jope
Journal:  Biol Psychiatry       Date:  1989-02-01       Impact factor: 13.382

7.  Subacute and chronic in vivo lithium treatment inhibits agonist- and sodium fluoride-stimulated inositol phosphate production in rat cortex.

Authors:  P P Godfrey; S J McClue; A M White; A J Wood; D G Grahame-Smith
Journal:  J Neurochem       Date:  1989-02       Impact factor: 5.372

8.  Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands.

Authors:  M J Berridge; C P Downes; M R Hanley
Journal:  Biochem J       Date:  1982-09-15       Impact factor: 3.857

9.  Effect of chronic lithium administration on adrenoceptor binding and adrenoceptor regulation in rat cerebral cortex.

Authors:  G Gross; C Dodt; G Hanft
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-03       Impact factor: 3.000

10.  Differentiation of alpha 1-adrenergic receptors linked to phosphatidylinositol turnover and cyclic AMP accumulation in rat brain.

Authors:  R D Johnson; K P Minneman
Journal:  Mol Pharmacol       Date:  1987-03       Impact factor: 4.436

View more
  2 in total

1.  Peripheral noradrenergic function during chronic lithium treatment in the rat.

Authors:  J P Finberg; I Kremer; I Spanir; R H Lenox; E Klein
Journal:  J Neural Transm Gen Sect       Date:  1992

2.  Mood stabilizer psychopharmacology.

Authors:  Todd D Gould; Guang Chen; Husseini K Manji
Journal:  Clin Neurosci Res       Date:  2002-11-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.